LINEZOLID | N021130 | PFIZER INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| N.D. Ill. | 2013-03-15 | Terminated 2013-12-19 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Close Consulting, LLC FDA-2025-P-1026 · 10 docket documents Close Consulting, LLC filed this petition pursuant to section 505(j)(2)(C) of the FDC Act and 21 CFR 314.93 requesting that the FDA determine that Linezolid Tablets for Oral Suspension, 600 mg are suitable for submission in an ANDA based on the reference listed drug ZYVOX Tablets, 600 mg (NDA N02113 | Suitability | 2025-04-01 | Open | Close Consulting, LLC |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$1.43
per ea
Lowest NADAC/Unit
$1.43
per ea
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 59762130702LINEZOLID 600 MG TABLET | $1.43 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.